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ABSTRACT
Objective:  Lower extremity lymphedema adversely affects quality of life by causing 
discomfort, impaired mobility and increased risk of infection. The goal of this study is to 
investigate factors that influence the likelihood of lymphedema in patients with endometrial 
cancer who undergo adjuvant radiation with or without chemotherapy.
Methods:  A retrospective chart review identified all stage I–III endometrial cancer patients 
who had a hysterectomy with or without complete staging lymphadenectomy and adjuvant 
radiation therapy between January 2006 and February 2013. Patients with new-onset 
lymphedema after treatment were identified. Logistic regression was used to find factors that 
influenced lymphedema risk.
Results:  Of 212 patients who met inclusion criteria, 15 patients (7.1%) developed new-onset 
lymphedema. Lymphedema was associated with lymph-node dissection (odds ratio [OR], 
5.6; 95% CI, 1.01 to 105.5; p=0.048) and with the presence of pathologically positive lymph 
nodes (OR, 4.1; 95% CI, 1.4 to 12.3; p=0.01). Multivariate logistic regression confirmed the 
association with lymph-node positivity (OR, 3.2; 95% CI, 1.0007 to 10.7; p=0.0499) when 
controlled for lymph-node dissection. Median time to lymphedema onset was 8 months 
(range, 1 to 58 months) with resolution or improvement in eight patients (53.3%) after a 
median of 10 months.
Conclusion:  Lymph-node positivity was associated with an increased risk of lymphedema 
in endometrial cancer patients who received adjuvant radiation. Future studies are needed 
to explore whether node-positive patients may benefit from early lymphedema-controlling 
interventions.
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INTRODUCTION
Lower-extremity lymphedema is a known possible complication of endometrial cancer 
treatment that adversely affects quality of life [1,2]. Prior single-institution retrospective 
studies have reported lymphedema rates that vary greatly from 2% to 47% [1-8]. Notably, the 
number of lymph nodes removed varied greatly among these studies, with the lowest rates 
of lymphedema (2.4% to 11.4%) reported in studies where most patients had fewer than 10 
lymph nodes removed, and the highest rates (27.2% to 47%) reported in studies where most 
patients had more than 20 lymph nodes removed [3-6,8,9]. A recent survey of the Australian 
National Endometrial Cancer Study Group found that 13% of 1,243 patients treated for 
endometrial cancer developed self-reported or physician-reported lymphedema. In that 
study, the absolute risk of lymphedema in patients with no lymph nodes removed was 8% or 
less whereas the risk in patients with more than 15 lymph nodes removed was over 30% [10]. 
In this study and in others, a variety of other risk factors for lymphedema after endometrial 
cancer treatment have also been suggested, including radiation, chemotherapy, and 
nonsteroidal anti-inflammatory drug use; however, the strength of correlation and magnitude 
of these effects are typically less pronounced than the effect of lymph node dissection [6,8,10].
Whether factors other than lymphadenectomy may increase the risk of lymphedema has not 
been well established. In addition, once lymphedema develops, the expected clinical course 
is not well understood. The goal of the current study is to investigate patient, disease, and 
treatment factors that may be associated with lymphedema development in endometrial 
cancer patients who received adjuvant external beam radiotherapy and vaginal brachytherapy 
after hysterectomy, and to characterize the clinical course of this complication.
MATERIALS AND METHODS
Retrospective chart review identified 222 patients with stage I–III endometrial cancer who 
received adjuvant radiation after hysterectomy between January 2006 and February 2013, 
were not on a trial of bevacizumab, and had more than 1 year of follow-up data available. Of 
these, 10 patients had disease recurrence less than 3 months after radiation therapy and were 
therefore excluded, resulting in the data from 212 patients being used for analysis.
The medical record of each patient was examined to collect patient characteristics (including 
age, body mass index [BMI] and Charlson comorbidity index), disease characteristics 
(including stage, grade, myometrial invasion, lymphovascular invasion, pelvic washings, 
and positive lymph nodes found upon surgery), detailed treatment parameters (including 
number of lymph nodes removed, total external beam radiation dose including a boost if 
present, vaginal brachytherapy dose, length of radiation treatment, and type of chemotherapy 
regimen), and disease outcomes (including disease recurrence and mortality).
All patients underwent computed tomography-based planning with custom immobilization. 
External beam radiation was administered in daily treatments 5 days per week in 1.8 Gy daily 
fractions to the pelvis with 15 MV photons; some patients also received concurrent 1.2 to 
1.5 Gy to the whole abdomen (anterior-posterior/posterior-anterior technique or intensity 
modulated radiation therapy [IMRT]) for 20 to 25 fractions with 6 MV. Patients with para-
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aortic nodal disease received IMRT consisting of 7 to 9 fields, using 6 MV photons with dose 
limits as previously described [11].
The medical record was also used to identify patients with new-onset lower extremity 
lymphedema, as described by the physician or reported by the patient. The medical records 
of each patient with lymphedema were carefully examined to confirm that the onset of this 
symptom was subsequent to cancer treatment and not attributable to an independent pre-
existing etiology, such as heart failure. Due to the retrospective nature of this study, precise 
measurements of lymphedema were not available. However, it is standard practice in our 
clinic to ask all patients who have had endometrial-cancer treatment whether they have noted 
new lower-extremity swelling as well as to formally evaluate this by both visual inspection 
and palpation.
For patients who developed new-onset lymphedema, the medical record was used to track 
the clinical course of this complication. Specifically recorded were: time from treatment 
completion to onset; subsequent progression, improvement or resolution (as documented 
by a physician at follow-up visits); time to resolution (if present); and the documented 
interventions used to treat lymphedema.
Statistical analyses were performed using JMP (SAS Institute, Cary, NC, USA). For each 
demographic, disease and treatment parameter, univariate logistic regression was used to 
estimate the odds ratio (OR) of association with lymphedema. For parameters that had a 
statistically significant (p<0.05) association with lymphedema, a multivariate logistic model 
was created using stepwise selection. In the final analysis, parameters were considered 
significant with a two-sided p<0.05. This study was approved by the Institutional Review 
Board of the Dana Farber/Brigham & Women’s Cancer Center.
RESULTS
1. Patient, disease, and treatment characteristics
The records of the 212 endometrial cancer patients who received adjuvant radiotherapy after 
hysterectomy and met the inclusion criteria were reviewed. Patient, disease, and treatment 
characteristics as well as disease outcomes are described in Table 1. The population 
represented a wide spectrum of intermediate- to high-risk disease. Most patients had either 
endometrioid or papillary serous histology (81.6%), which manifested as mostly grade 2–3 
disease (76.9%). Approximately half of patients had lymphovascular invasion and half had 
deep (more than 50%) myometrial invasion. Pelvic lymph-node dissection was performed 
in 75% (n=159) with a median of 6.5 (range, 0 to 58) pelvic lymph nodes removed. Notably, 
only 11.3% (n=24) had more than 20 lymph nodes removed. All patients received adjuvant 
radiation, consisting most commonly of 45 Gy external beam radiotherapy (80.7%) followed 
by 16 Gy (4 fractions of 4 Gy) vaginal brachytherapy (94.8%). Adjuvant chemotherapy was 
received by slightly more than half of patients, with carboplatin and taxol being used most 
commonly. Disease recurred in 23.6% of patients, with many having simultaneously detected 
recurrence at multiple sites. Overall, no patients had an isolated vaginal recurrence, 4.7% had 
recurrence in a pelvic lymph node, 9.0% had regional recurrence (para-aortic or pelvic side-
wall), and 17.0% had recurrence at a distant site.
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Table 1.  Study population demographic, disease, treatment, and outcome characteristics
Characteristic Value
Study population
   Enrollment period 2006–2013
   Total patients receiving treatment 264
   Patients excluded from analysis 52
      <1 yr follow-up from diagnosis 24
      Stage IV disease on presentation 14
      Recurrence <3 mo after treatment 10
      Patients enrolled in bevacizumab trial 4
   Total patients eligible for analysis 212
Patient characteristic
   Age (yr) 64 (34–91)
   Body mass index (kg/m2) 29.8 (17–63)
   Charlson comorbidity index 0 (0–4)
   Follow-up from diagnosis (mo) 35 (12–84)
Treatment characteristic
   Lymph node dissection 159 (75.0)
      0 53 (25.0)
      1–9 67 (31.6)
      ≥10 92 (43.4)
   Adjuvant chemotherapy 120 (56.6)
      Carboplatin/paclitaxel 98 (46.2)
      Oxaliplatin/gemcitabine 10 (4.7)
      Concurrent cisplatin/radiation 12 (5.7)
   External beam radiation dose (Gy) 212 (100)
      41.4   1 (0.5)
      45 171 (80.7)
      50–50.4 21 (9.9)
      54–64.8 19 (9.0)
   Vaginal brachytherapy (Gy) 212 (100)
      12–15 10 (4.7)
      16 201 (94.8)
      18 1 (0.5)
   Time elapsed during radiation (day) 56 (38–103)
Disease characteristic
   Initial FIGO stage
      I 72 (34.0)
      II 48 (22.6)
      IIIA/B 37 (17.5)
      IIIC 55 (25.9)
   Initial histology
      Endometrioid 127 (59.9)
      Uterine papillary serous 46 (21.7)
      Uterine clear cell 7 (3.3)
      Uterine carcinosarcoma 26 (12.3)
      Uterine squamous 6 (2.8)
   Initial grade
      1 49 (23.1)
      2 57 (26.9)
      3 106 (50.0)
   Myometrial invasion (%)
      0–25 70 (33.0)
      26–50 42 (19.8)
      51–75 53 (25.0)
      >75 47 (22.2)
   Lymphovascular invasion 16 (54.7)
   Positive pelvic washings 35 (16.5)
   Positive pelvic lymph nodes 52 (24.5)
   Positive para-aortic lymph nodes 12 (5.7)
Disease outcome
   Disease recurrence at any site 50 (23.6)
      Pelvic node recurrence 10 (4.7)
   Mortality 26 (12.3)
      Cancer related mortality 20 (9.4)
Values are presented as number, median (range), or number (%).   
FIGO, International Federation of Gynecology and Obstetrics.
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2. Onset and management of lymphedema
With a median follow-up time of 35 months (range, 12 to 84 months), 7.1% of patients 
(n=15) developed new-onset lower-extremity lymphedema. Table 2 describes the detailed 
demographic, disease, and treatment characteristics of each patient who developed 
lymphedema as well as the clinical course of this symptom. The median time to onset of 
documented lymphedema, measured from the last day of radiation therapy, was 8 months 
(range, 1 to 58 months) with six patients (40.0%) having complete resolution of their 
lymphedema a median of 10 months (range, 4 to 15 months) later, two patients (13.3%) 
having some improvement, six patients (40.0%) having stable symptoms, and one patient 
(6.7%) experiencing worsening lymphedema over time. Two-thirds (n=10) of the patients 
with lymphedema were documented to have received compression stockings and 3 were also 
documented to have received therapeutic lower-extremity massage. Information regarding 
the details of the massage technique were not available. However, no correlation was found 
between documented intervention and improvement or resolution of symptoms. There was 
no difference in the characteristics of patients who had resolution of symptoms and those 
who did not; characteristics examined included BMI, age, Charlson comorbidity index and 
time interval from treatment completion to lymphedema onset.
3. Incidence and prevalence of lymphedema
The incidence and prevalence of lymphedema over time is illustrated in Fig. 1. Of the 
15 patients who developed lymphedema after treatment, 80.0% (n=12) developed the 
symptom within 18 months of completing therapy. Three additional patients developed 
new lymphedema later (26, 48, and 58 months after treatment completion). An early peak 
prevalence of lymphedema occurred by 15 months after treatment followed by a decline that 
plateaued at 25 months and subsequently slowly rose at much later time points to a final peak 
prevalence of 4.3% at 5 years after treatment.
Table 2.  Detailed characteristics of patients with new-onset lymphedema
Patient Disease characteristic Treatment characteristic Lymphedema course
ID Age 
(yr)
Follow-up 
(mo)
Histology Grade Stage MI 
(%)
LVI Recurrence 
site (mo)
No. of pelvic 
LN dissected
(+) 
Pelvic LN
EB dose 
(Gy)
Chemotherapy Time to 
onset (mo)
Change 
in LE
Tx Duration 
(mo)
1 68 79 PS 3 IA 25 N Lung (49) 6 0 45* N 1 Resolve Y 11
2 77 30 CS 3 IA 30 Y N 11 0 45* carb/tx 7 Resolve N 15
3 77 74 CS 3 IA 33 N N 24 0 45* oxalip/gem 26 Worsen Y >38
4 66 26 Endo 1 IB 90 Y N 0 0 45* N 15 Improve N >7
5 86 41 CS 3 IB 60 N N 1 0 45* N 6 Resolve Y 9
6 76 59 CC+Endo 3 IB 90 Y N 16 0 45* N 15 Resolve N 4
7 53 48 Endo 3 IIIA 5 N N 7 0 45* carb/tx 13 Stable Y >34
8 61 64 Endo 1 IIIC1 40 Y N 5 1 45† carb/tx 48 Improve N >3
9 58 70 Endo 2 IIIC1 40 N N 18 1 45* carb/tx 4 Resolve Y 6
10 59 69 Endo 1 IIIC1 55 Y N 19 1 45† N 58 Stable Y >11
11 63 33 Endo 1 IIIC1 50 Y N 11 1 45* carb/tx 1 Resolve Y 13
12 72 24 PS+CC 3 IIIC1 65 Y Pelvic LN 
(16)
15 2 61.2‡ carb/tx 8 Stable Y >7
13 56 29 Endo 2 IIIC1 0 N N 29 2 45* carb/tx 1 Stable Y >19
14 78 24 CS 3 IIIC1 95 N Lung (16) 22 3 50.4* carb/tx 3 Stable Y >9
15 61 43 Squamous 3 IIIC2 100 Y N 3 3 55.8‡ carb/tx 15 Stable N >17
carb/tx, carboplatin/paclitaxel; CC, clear cell; CS, carcinosarcoma; EB, external beam radiotherapy; Endo, endometrioid; LE, lymphedema; LN, lymph nodes; 
LVI, lymphovascular invasion; MI, myometrial invasion; N, no or absent; oxalip/gem, oxaliplatin/gemcitabine; PS, papillary serous; Tx, lymphedema treatment; Y, 
yes or present; (+), tumor positive. 
*4-field pelvis. †Whole abdomen anterior-posterior/posterior-anterior. ‡Intensity modulated radiation therapy to pelvis and para-aortic nodes.
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4. Risk factors for lymphedema
Univariate logistic regression was performed to investigate possible factors that influence 
the risk of lymphedema after endometrial-cancer treatment. Table 3 illustrates the ORs of 
lymphedema by disease and treatment characteristic tested. Having a more complete pelvic 
lymph node dissection (defined as 10 or more lymph nodes removed) was associated with 
an increased risk of lymphedema when compared to no dissection (OR, 5.6; 95% CI, 1.01 to 
105.5; p=0.048). However, a less complete lymph-node dissection (defined as 1 to 9 lymph 
nodes removed) was not associated with increased risk (p=0.14). The cut-off of 10 lymph 
nodes as the break-point for analysis was chosen because the mean number of lymph nodes 
removed in our study was 9.7; 56.6% of patients who had any nodes dissected had 1 to 9 
lymph nodes removed and 43.4% had 10 or more removed (Table 1). Of the 15 patients who 
developed lymphedema, 1 (6.7%) had no lymph nodes removed, 5 (33.3%) had fewer than 10 
lymph nodes removed, and 9 (60.0%) had 10 or more lymph nodes removed.
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Fig. 1.  Incidence and prevalence of lymphedema. Bar graph shows the percent of patients with new onset 
lymphedema during each 6-month interval after adjuvant therapy completion. Line graph shows the prevalence 
of lymphedema during the same time period.
Table 3.  Predictors of lymphedema by univariate and multivariate models
Characteristic Odds ratio
Univariate model Multivariate model
Patient characteristic
   Age (yr), >70 vs. ≤70 0.8 (0.2–2.6)
   Body mass index (kg/m2), >25 vs. ≤25 1.0 (0.2–3.8)
   Charlson comorbidity index, >2 vs. 0–2 1.7 (0.2–14.5)
Disease characteristic
   Lymphovascular invasion, yes vs. no 0.9 (0.3–2.7)
   Disease recurrence, yes vs. no 0.80 (0.2–2.9)
   Pelvic lymph nodes, with disease vs. no disease 4.1 (1.4–12.3)* 3.2 (1.0007–10.7)*
Treatment characteristic
   LND, ≥10 LN removed vs. no LN removed 5.6 (1.01–105.5)* 3.1 (0.4–26.8)
   External beam radiation (Gy), >50.4 vs. ≤50.4 1.7 (0.3–7.1)
   Adjuvant chemotherapy, yes vs. no 1.5 (0.5–4.4)
LN, lymph node; LND, lymph node dissection.  
*Represents odds ratio for which p<0.05.
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The presence of at least one tumor-positive pelvic lymph node was also associated with 
increased lymphedema risk (OR, 4.1; 95% CI, 1.4 to 12.3; p=0.01). Specifically, 4.3% of 
patients with negative pelvic lymph nodes developed lymphedema whereas 15.7% of patients 
with positive pelvic lymph nodes did. However, the presence of more positive lymph nodes 
did not increase the likelihood of lymphedema (OR, 1.08 per additional positive lymph node; 
95% CI, 0.79 to 1.34). Of note, the presence of positive pelvic lymph nodes was not associated 
with an increased risk of disease recurrence after treatment (p=0.40).
A multivariate regression model was constructed to include lymph node positivity and lymph 
node dissection as possible predictors of lymphedema risk. In this model, lymph node 
positivity continued to exhibit a statistically significant association with lymphedema (OR, 
3.2; 95% CI, 1.0007 to 10.7; p=0.0499) while the association of lymph-node dissection with 
lymphedema risk was no longer statistically significant (p=0.27).
Notably, in this population of patients with relatively high-risk endometrial cancer, including 
43.4% (n=92) with stage III disease and 40.1% (n=85) with non-endometrioid histology, disease 
recurred in only 23.6% (n=50), with isolated pelvic recurrence occurring in only 1.4% (n=3).
DISCUSSION
This series found that patients who have at least one pathologically positive lymph node at 
diagnosis have a higher risk of lymphedema, even when controlling for pelvic lymph node 
dissection. While this observation has not been previously reported in studies of endometrial 
cancer, there is precedent in the breast cancer literature, where the number of positive axillary 
lymph nodes has been found to be associated with the risk of upper-extremity lymphedema, 
independent of the number of lymph nodes dissected [12]. In a study from Mayo Clinic where 
591 endometrial cancer patients responded to a mail-in survey and 17% reported a diagnosis 
of lymphedema, the authors found an association between stage III–IV disease (vs. stage I–II 
disease) and lymphedema risk, though this did not hold up with multivariate analysis [8].
While the mechanism by which lymph-node positivity increases the risk of lymphedema is 
not known, recent molecular imaging techniques have shown that in the axilla, the presence 
of tumor cells in sentinel lymph nodes can impede lymphatic flow [13]. This observation 
suggests that the presence of tumor cells in the pelvic lymph nodes might also disrupt the 
normal lymphatic architecture, resulting in altered lymphatic drainage from the lower 
extremities. However, given that there is no association between disease recurrence and 
lymphedema risk, it seems unlikely that the mechanism by which lymph-node positivity 
predisposes patients to lymphedema is by serving as a nidus for disease recurrence, acting 
by mass effect to obstruct lymphatic flow. Rather, we hypothesize that the presence of tumor 
cells in the lymphatic space may cause irreversible changes to the extracellular environment, 
thereby altering the local architecture. The presence of positive pelvic lymph nodes likely 
increases the probability of microscopic tumor implants in the pelvic lymphovascular bed 
that were not observed during surgical staging. Adjuvant radiation may effectively kill these 
microscopic tumor cells leading to regions of lymphovascular fibrosis, further increasing the 
risk of lymphedema. The surprising observation that there is no association between pelvic 
lymph-node positivity and risk of disease recurrence likely speaks to the efficacy of adjuvant 
radiotherapy in treating even high-risk patients.
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Several previous studies with conflicting results have investigated a possible association 
between radiation treatment and lymphedema. Some have suggested that postoperative 
radiotherapy increases the risk of lymphedema. Notably, however, the majority of patients in 
those studies had more than 20 nodes removed, which may be higher than typical of many 
institutions [4,6,8,14]. In contrast, neither van de Poll-Franse et al. [15], with a median of 
13 nodes (range, 1 to 42 nodes) removed, nor Achouri et al. [5], with a mean of 12.0 nodes 
(standard deviation, 5.9) removed, found a relationship between adjuvant radiotherapy and 
lymphedema risk using either physician-reported or patient-reported outcome data. While all 
patients in our series received adjuvant radiation, the dose or length of treatment time did not 
have a significant effect on lymphedema rates.
While we found only a weak association of lymphedema with lymph-node dissection on 
univariate analysis, the average number of nodes dissected in our patient population is lower 
(mean, 9.7) than that of series reporting an increased association. For example, in two 
Japanese series with higher rates (27.2% to 37.8%) of lymphedema, 0.7% to 9.8% of patients 
received adjuvant radiation and more than 90% had 20 or more lymph nodes removed [4,6]. 
Interestingly, the few patients from the Japanese series with fewer than 10 lymph nodes 
removed had a lymphedema rate of only 10% [6]. In one series from Memorial Sloan-Kettering, 
the lymphedema rate was found to be 3.4% and was limited exclusively to women who had 
more than 10 lymph nodes removed [3]. Our current series reports a mean of 9.7 lymph nodes 
removed and a 7.1% lymphedema rate. Similarly, a report by Achouri et al. [5] found that in the 
context of a mean 12.0 lymph nodes removed, the lymphedema rate was 11.4%.
Given that in this series only 11.3% of patients had more than 20 lymph nodes removed, 
the less extensive dissection may account for the weaker association between dissection and 
lymphedema. By not having lymph node dissection be an overwhelming explanatory variable, 
this study is uniquely positioned to find the novel factor of nodal positivity influencing 
lymphedema risk. Despite the relatively limited lymph node dissection performed in this 
population of high-risk patients, the outcomes in terms of lymphedema (7%) and disease 
recurrence (23.6%) remained quite strong.
In this study, more than 50% of lymphedema cases (n=8) improved or resolved by 15 months. 
No association was found between documented interventions to treat the new-onset 
lymphedema and improvement or resolution of the symptoms. Notably, one-third of patients 
with lymphedema did not receive any intervention. Of those who did, most tried  
compression stockings.
The literature on lower extremity lymphedema treatment and its efficacy is not yet robust. A 
systematic review of the literature for secondary lower extremity lymphedema management 
in cancer patients was unable to reach any conclusions about best practice recommendations 
[16]. In general, the most commonly recommended intervention is compression stockings, 
which have shown some efficacy for decades [17-20]. However, more recent work has 
questioned whether class-II compression stockings have much effect [21]. Some studies 
suggest intermittent pneumatic compression may be more effective in mobilizing stagnant 
lymphatic fluid [18,22]. The best data seem to support complex decongestion therapy, 
but this intensive regimen of physical therapy, massage, and other adjuncts has significant 
resource demands and is not available to all patients [23-25]. The role of physical therapy 
for lower extremity lymphedema is not well defined. Various surgical interventions are also 
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possible, including lymphatico-venous anastomoses; however, given their invasive nature, 
these interventions are typically undertaken in only the most problematic and refractory cases 
[26,27]. Future studies into early and systematic implementation of interventions including 
exercise and compression devices in endometrial-cancer patients found to have lymph-node 
positivity may be effective in decreasing the burden of posttreatment lymphedema.
This analysis was performed on a retrospectively collected single-institution dataset; as 
such, the results and conclusions described are hypothesis-generating rather than definitive. 
In addition, it was not the practice at our institution during the period under review to 
formally measure the degree of lymphedema during patient visits despite the existence of 
multiple validated methods for doing so [28]. As a result, we relied on the documentation 
of physician- or patient-reported lymphedema after treatment. Similarly, the resolution, 
improvement or progression of lymphedema was recorded only as qualitatively reported 
by physician or patient and documented in the medical record. For this reason the precise 
numbers documented may be only an approximation of the “true” lymphedema rate and 
course. However, our study is not unique is this respect and it is reassuring that multiple prior 
studies of endometrial-cancer patients treated similarly to our own have reported very similar 
overall rates of lymphedema [3,5].
In conclusion, this study found that 7.1% of 212 endometrial-cancer patients receiving 
adjuvant pelvic radiotherapy with or without chemotherapy developed new-onset 
lower-extremity lymphedema after completion of treatment. The presence of at least 
one pathologically positive node at diagnosis was associated with an increased risk of 
lymphedema, even when controlling for pelvic lymph-node dissection. These findings are 
significant in suggesting that patients with stage III disease may benefit from more aggressive 
monitoring and potentially prophylactic measures to limit the risk of long-term lymphedema. 
However, future studies are needed to determine which such interventions are likely to be 
most effective and whether targeting their implementation to the highest risk groups will 
lower overall post-treatment lymphedema rates.
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